Polyrizon Ltd. (PLRZ) Stock

Polyrizon Ltd. (PLRZ) is a Healthcare stock trading at $12.91 (as of 2026-06-18), with a market capitalization of $15.10M and a trailing P/E of 2.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Polyrizon Ltd. develops medical device hydrogels delivered as nasal sprays in Israel, designed to act as a barrier against viruses and allergens contacting nasal epithelial tissue. Its pipeline includes nasal formulations PL-14 for nasal allergies and PL-15 and PL-16 for COVID-19 and influenza.

Valuation — source: SEC EDGAR (first-party)
Price$12.91
Market Cap$15.10M
P/E Ratio2.7
EV / EBITDA-3.4
Price / Book1.01
DCF Value (model)$-47.19
DCF Upside vs Price-465.5%
Profitability & Growth — source: SEC EDGAR
Return on Equity-15.9%
Current Ratio29.03
Valuation vs Sector & Industry
Stock P/E2.7
Sector P/E (Healthcare)20.9
Industry P/E (Medical Equipment)31.7
vs Sector-87.1%
vs Industry-91.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFNY Investment Advisers, LLC ($283000.00)
Institutional Holders Tracked7
Company
SectorHealthcare
IndustryMedical Equipment
CEOTomer Izraeli
Employees2
CountryIL
IPO Date2024-10-29

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Adagio Medical Holdings, Inc. (ADGM)
  • Milestone Scientific Inc. (MLSS)
  • IRIDEX Corporation (IRIX)
  • Bionano Genomics, Inc. (BNGO)
  • Sintx Technologies, Inc. (SINT)
  • Intelligent Bio Solutions Inc. (INBS)
  • Check-Cap Ltd. Ordinary Share (MBAI)
  • Astrotech Corporation (ASTC)
PLRZ earnings history · PLRZ institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.